Optimizing cell lines for a Hepatitis B vaccine
Task V24: Cell line optimization and pre-master bank generation for a Hepatitis B Virus (HBV) vaccine
['FUNDING_OTHER'] · INTERNATIONAL AIDS VACCINE INITIATIVE · NIH-10269959
This study is working on making better cell lines to help create a new vaccine for Hepatitis B, so we can fight this virus and related diseases more effectively.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INTERNATIONAL AIDS VACCINE INITIATIVE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10269959 on ClinicalTrials.gov |
What this research studies
This research focuses on improving cell lines used to produce a vaccine for Hepatitis B Virus (HBV). It involves developing and optimizing these cell lines to ensure they can effectively produce vaccine components under strict regulatory standards. The project includes planning, feasibility assessments, and compliance with good manufacturing practices (cGMP) for clinical studies. By enhancing the production process, the research aims to facilitate the introduction of a new vaccine that can combat HBV and related infectious diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of Hepatitis B infection, including those with chronic liver disease or those in high-prevalence areas.
Not a fit: Patients who are already vaccinated against Hepatitis B or those with no risk factors for the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and accessible vaccine for Hepatitis B, potentially reducing the incidence of this infectious disease.
How similar studies have performed: Previous research has shown success in optimizing cell lines for vaccine production, indicating that this approach has potential for effective outcomes.
Where this research is happening
NEW YORK, UNITED STATES
- INTERNATIONAL AIDS VACCINE INITIATIVE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HASSEL, THOMAS — INTERNATIONAL AIDS VACCINE INITIATIVE
- Study coordinator: HASSEL, THOMAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Communicable Diseases, Infectious Disease Pathway, Infectious Diseases, Infectious Disorder